PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022. To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170313 For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

1. PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Germany Drug
Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the
gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and
effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is
dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis
Menveo, account for the vast majority of global sales, with the US adolescent market being the key target
segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the
launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that
better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market
share during 2012-2022.
GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged
for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate kit, and
Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient
share is largely determined by prescriber preference in Germany and therefore is not expected to change
drastically during the forecast period.
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key
drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Germany from 2012-2022. Analysis of the impact of key events as well the
drivers and restraints affecting Germany Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of
the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively
plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make
more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales
forecast for drugs from 2012-2022 in Germany
table Of Contents
1 Table Of Contents 1
1.1 List Of Tables 3
1.2 List Of Figures 3
2 Executive Summary 4
2.1 Sales For Meningococcal Vaccine In Germany 4
2.2 What Do The Physicians Think? 6
3 Introduction 7
PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022

2. 3.1 Catalyst 7
3.2 Related Reports 8
3.3 Upcoming Related Reports 10
4 Disease Overview 10
4.1 Etiology And Pathophysiology 11
4.1.1 Etiology 11
4.1.2 Pathophysiology 12
4.2 Symptoms 13
4.3 Prognosis 14
5 Disease Management 14
5.1 Meningococcal Immunization Policy 15
5.2 Germany 17
5.2.1 Meningococcal Immunization Recommendations And Policies 17
5.2.2 Clinical Practice 18
6 Competitive Assessment 18
6.1 Overview 18
6.2 Strategic Competitor Assessment 18
6.3 Product Profiles Major Brands 20
6.3.1 Menveo 20
6.3.2 Nimenrix 24
6.3.3 Meningitec 27
6.3.4 Menjugate 30
6.3.5 Neisvac-c 33
6.3.6 Bexsero 35
7 Opportunity And Unmet Need 37
7.1 Overview 37
7.2 Unmet Needs 38
7.2.1 Unmet Need: Protection Against Serogroup B Disease 38
7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 38
7.2.3 Unmet Need: More Cost-effective Vaccines 40
7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 40
7.2.5 Unmet Need: Immunogenic Infant Vaccines 42
7.2.6 Unmet Need: Improved Vaccination Coverage Rates 43
7.2.7 Unmet Need: Increased Patient Awareness And Education 44
7.3 Unmet Needs Gap Analysis 45
7.4 Opportunities 46
7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 46
7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 47
7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022

3. Markets 48
8 Pipeline Assessment 48
8.1 Overview 48
8.2 Promising Vaccines In Clinical Development 48
8.2.1 Mnb Rlp2086 52
8.3 Promising Vaccines In Early Clinical Development 56
8.3.1 Meninge Acyw Conj. 56
8.3.2 Menabcwy 60
8.3.3 Menc Conjugate 62
8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 65
9 Market Outlook 67
9.1 Germany 67
9.1.1 Forecast 67
9.1.2 Key Events 70
9.1.3 Drivers And Barriers 71
10 Appendix 72
10.1 Bibliography 72
10.2 Abbreviations 82
10.3 Methodology 84
10.4 Forecasting Methodology 84
10.4.1 Vaccine Coverage 85
10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 85
10.4.3 Vaccines Included 86
10.4.4 Key Launch Dates 87
10.4.5 General Pricing Assumptions 88
10.4.6 Individual Vaccine Assumptions 89
10.4.7 Pricing Of Pipeline Agents 94
10.5 Physicians And Specialists Included In This Study 95
10.6 About The Authors 98
10.6.1 Authors 98
10.6.2 Reviewers 98
10.6.3 Global Head Of Healthcare 98
10.7 About Globaldata 99
10.8 Contact Us 99
10.9 Disclaimer 99
Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most
comprehensive collection of market research reports. Marketresearchreports.biz services are especially
designed to save time and money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription access and consulting services.
We serve all sizes and types of companies spanning across various industries.
PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022

4. Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.com
Website: www.marketresearchreports.biz
PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022